Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASHGlobeNewsWire • 05/06/21
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH CongressGlobeNewsWire • 04/29/21
DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical's Lead Drug, CRV431GlobeNewsWire • 03/23/21
ENDRA Life Sciences and Hepion Pharmaceuticals Partner to Drive Efficiencies in NASH Clinical TrialsAccesswire • 03/18/21
Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor ConferencesAccesswire • 01/05/21
Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASHAccesswire • 12/29/20
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASHAccesswire • 12/29/20
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19Accesswire • 12/22/20
Are Options Traders Betting on a Big Move in Hepion (HEPA) Stock?Zacks Investment Research • 12/09/20
Hepion Pharmaceuticals: CRV431 Continues To Progress In Early Phase NASH Clinical TrialsSeeking Alpha • 06/30/20
Hepion Pharmaceuticals And Neoleukin Therapeutics: Two Micro Cap Pharmaceutical Stocks Priced For "Non Success" With Promising DrugsSeeking Alpha • 11/26/19
Hepion Pharmaceuticals And Neoleukin Therapeutics: 2 Micro-Cap Pharmaceutical Stocks Priced For 'Non Success' With Promising DrugsSeeking Alpha • 11/26/19
Hepion Pharmaceuticals' stock rockets after upbeat results of preclinical study of liver cirrhosis treatmentMarket Watch • 11/21/19